Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma

Journal of Hepatology

Volumn 66, Issue 3, 2017, Pages 545-551

  Duffy, Austin G ^a   Ulahannan, Susanna V ^a   Makorova Rusher, Oxana ^a   Rahma, Osama ^a   Wedemeyer, Heiner ^b   Pratt, Drew ^a   Davis, Jeremy L ^a   Hughes, Marybeth S ^a   Heller, Theo ^c   ElGindi, Mei ^a   Uppala, Ashish ^a   Korangy, Firouzeh ^a   Kleiner, David E ^a   Figg, William D ^a   Venzon, David ^a   Steinberg, Seth M ^a   Venkatesan, Aradhana M ^c   Krishnasamy, Venkatesh ^c   Abi Jaoudeh, Nadine ^c   Levy, Elliot ^c   Wood, Brad J ^c   Greten, Tim F ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Hepatocellular carcinoma; Immune; Immune checkpoint; Liver cirrhosis; T Lymphocytes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLOBETASOL; DIPEPTIDYL CARBOXYPEPTIDASE; HEPATITIS B SURFACE ANTIGEN; PRAMOCAINE; PREDNISONE; TICILIMUMAB; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; COLONOSCOPY; CRYOABLATION; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERTENSION; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RADIOFREQUENCY ABLATION; RASH; SIDE EFFECT; THYROID DISEASE; TREATMENT RESPONSE; TUMOR ABLATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; VIRUS LOAD; VIRUS REPLICATION; X-RAY COMPUTED TOMOGRAPHY; ABLATION THERAPY; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; LIVER TUMOR; MIDDLE AGED;

ABLATION TECHNIQUES; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 85007494451     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.10.029     Document Type: Article

References (23)

1. [1] at http://globocan.iarc.fr.
2. [2] European Association for Study of Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 48 (2012), 599–641.
3. [3] Llovet, J.M., Ricci, S., Mazzaferro, V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
4. [4] Cheng, A.L., Kang, Y.K., Chen, Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
5. [5] Greten, T.F., Duffy, A.G., Korangy, F., Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res 19 (2013), 6678–6685.
6. [6] Korangy, F., Ormandy, L.A., Bleck, J.S., et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10 (2004), 4332–4341.
7. [7] Mizukoshi, E., Nakamoto, Y., Arai, K., et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 53 (2011), 1206–1216.
8. [8] Zerbini, A., Pilli, M., Laccabue, D., et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 138 (2010), 1931–1942.
9. [9] Ayaru, L., Pereira, S.P., Alisa, A., et al. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol 178 (2007), 1914–1922.
10. [10] Hiroishi, K., Eguchi, J., Baba, T., et al. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol 45 (2010), 451–458.
11. [11] Nobuoka, D., Motomura, Y., Shirakawa, H., et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol 40 (2012), 63–70.
12. [12] Hansler, J., Wissniowski, T.T., Schuppan, D., et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 12 (2006), 3716–3721.
13. [13] Sangro, B., Gomez-Martin, C., de la Mata, M., et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59 (2013), 81–88.
14. [14] Maecker, H.T., McCoy, J.P., Nussenblatt, R., Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 12 (2012), 191–200.
15. [15] Llovet, J.M., Hernandez-Gea, V., Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 20 (2014), 2072–2079.
16. [16] Makarova-Rusher, O.V., Medina-Echeverz, J., Duffy, A.G., Greten, T.F., The yin and yang of evasion and immune activation in HCC. J Hepatol 62 (2015), 1420–1429.
17. [17] Chen, M.S., Li, J.Q., Zheng, Y., et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243 (2006), 321–328.
18. [18] Feng, K., Yan, J., Li, X., et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 57 (2012), 794–802.
19. [19] Llovet, J.M., Real, M.I., Montana, X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002), 1734–1739.
20. [20] Mizukoshi, E., Yamashita, T., Arai, K., et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 57 (2013), 1448–1457.
21. [21] Waitz, R., Solomon, S.B., Petre, E.N., et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 72 (2012), 430–439.
22. [22] den Brok, M.H., Sutmuller, R.P., Nierkens, S., et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res 66 (2006), 7285–7292.
23. [23] Johnson, E.E., Yamane, B.H., Buhtoiarov, I.N., et al. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res 15 (2009), 4875–4884.